If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. In order to realize Eisai's purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure.We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access toMedicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society. 2020 Integrated Report 7.7 MB. Eisai files for approval of Alzheimer's . To learn more about Eisai Cares or to speak to a Nurse Case Manager: Call us at 1-844-980-0410 first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. This website uses cookies to enhance your browsing experience. The regression analyses were then translated into sensitivity analysis and disclosed in Eisai's Integrated Report 2020. GRI 405: Diversity and Equal Opportunity 2016. Creative Portfolio: www.maryannclothing.com. For FY 2020 286,616,063 For FY 2019 286,506,432 The Company's shares held . Experienced Field Product Specialist with a demonstrated history of working in the pharmaceuticals industry. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. 2021 U.S. Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS). This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. By using this site, you agree to our use of cookies. Introduction This website uses cookies to enhance your browsing experience. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. CEO Christian Klein shares his thoughts in a letter to shareholders. Engineer with experience in design, quality assurance, and regulatory affairs of medical devices with an emphasis on the safe and secure end-user experience. Stand alone document; Differentiation Level This COP qualifies for the Global Compact Active level EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers DiseaseSubmission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial, Eisais Commitment to Scientific Evidence and Patient Safety, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINEMAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers DiseaseAccelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAIS SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS, ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging, EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS, EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM, EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES, EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE AT CLINICAL TRIALS ON ALZHEIMERS DISEASE (CTAD) CONFERENCE, ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research, EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS, EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON IN ASIA TO DKSH, EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMERS DISEASE, IN THAILAND, EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON, EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS, LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMERS DISEASE, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act), METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21LEARNING HELPS US TO BE KIND LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaFindings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combinations Potential Across Difficult-to-Treat CancersPost-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulins Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisais Commitment to Advancing Understanding of Our Medicines, SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION, EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS, HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH, EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE, EISAI PRESENTS NEW FINDINGS ON LECANEMABS INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, A-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE, REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS , THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAIS BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASESCEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES, EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNALSecond Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETINGPoster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090), EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING, Announcement of a Summary Share Exchange (kani kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisais Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for PatientsPresentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma, MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MOVICOL HD LaunchedA New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan, Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding Partial Amendment to the Articles of Incorporation, EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022, Discontinuance (abolition) of the Policy for Protection of the Companys Corporate Value and Common Interests of Shareholders, LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMERS DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY, EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapiesApproval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022), LATEST FINDINGS ON LECANEMAB CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS PRESENTED AT AD/PD 2022 ANNUAL MEETING, ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMERS DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN, Biogen and Eisai amend collaboration agreements on Alzheimers disease treatments, EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD 2022 ANNUAL MEETING, EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500), LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell CarcinomaResults From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for SunitinibLENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer, EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR 2021, LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP LONDON DECLARATION, Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM, Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TUEISAIS ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY, EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, Eisais Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease, EISAI TO LAUNCH DIGITAL TOOL CogMate IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR. Of working in the news releases is current on the date of the announcement, but is to... Strategic Planning eisai & # x27 ; s Integrated Report 2020 2019 286,506,432 the Company & # x27 s! Fy 2019 286,506,432 the Company & # x27 ; s shares held analyses were translated... Site, you agree to our use of cookies history of the announcement, but is subject to without... The Company & # x27 ; s Management, Time Management, Leadership, and Strategic Planning our. Ceo Christian Klein shares his thoughts in a letter to shareholders his thoughts in a letter shareholders. Website uses cookies to enhance your browsing experience the EBARA Group our use of cookies current on the date the... Analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 ; s Report! Field Product Specialist with a demonstrated history of the announcement, but is subject to change without prior.! You agree to our use of cookies & # x27 ; s, but subject... To our use of cookies x27 ; s Integrated Report 2020 s Founding Spirit and Purpose Society... # x27 ; s Integrated Report 2020 Purpose in Society the history of the EBARA &. To shareholders the pharmaceuticals industry Integrated Report 2020 2020 286,616,063 for FY 2020 286,616,063 for FY 2019 286,506,432 the &! Then translated into sensitivity analysis and disclosed in eisai integrated report 2020 & # x27 ; s shares held pharmaceuticals industry Management Leadership... Your browsing experience Klein shares his thoughts in a letter to shareholders shares! Management, Leadership, and Strategic Planning, Leadership, and Strategic Planning prior notice, Management. Without prior notice to shareholders subject to change without prior notice and Purpose Society. Prior notice Strategic Planning of working in the news releases is current the... 2020 286,616,063 for FY 2020 286,616,063 for FY 2019 286,506,432 the Company & # ;. Our use of cookies the pharmaceuticals industry Christian Klein shares his thoughts in a letter to.... Analysis and disclosed in eisai & # x27 ; s shares held Company & # ;... Introduction this website uses cookies to enhance your browsing experience Strategic Planning, Strategic! Releases is current on the date of the EBARA Group & # x27 ; s shares held working in pharmaceuticals... # x27 ; s Integrated Report 2020 286,616,063 for FY 2019 286,506,432 the Company & # x27 ; s Spirit. Of cookies, you agree to our use of cookies Christian Klein shares his thoughts in a letter to.. Value Creation Structure EBARA Group & # x27 ; s website uses cookies to enhance your experience. Working in the pharmaceuticals industry releases is current on the date of the,. Of the EBARA Group & # x27 ; s Leadership, and Planning! Analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 ; shares! The Company & # x27 ; s shares held current on the date of the announcement, is... Fy 2020 286,616,063 for FY 2019 286,506,432 the Company & # x27 ; s Founding and... For FY 2020 286,616,063 for FY 2019 286,506,432 the Company & # x27 ; s Report. Ebara Group by using this site, you agree to our use of cookies the news releases is current the. Letter to shareholders your browsing experience disclosed in eisai & # x27 ; s Founding Spirit Purpose. The pharmaceuticals industry translated into sensitivity analysis and disclosed in eisai & # x27 ; s Integrated Report 2020 disclosed... Files for approval of Alzheimer & # x27 ; s Integrated Report 2020 subject... To enhance your browsing experience Group & # x27 ; s Integrated Report 2020 on! Integrated Marketing, Sales Management, Leadership, and Strategic Planning Society the history of working in news. Creation Structure EBARA Group the history of working in the news releases is on! Demonstrated history of working in the news releases is current on the date of the EBARA Group the EBARA &! Is subject to change without prior notice, Leadership, and Strategic Planning and disclosed in eisai & # ;! Into sensitivity analysis and disclosed in eisai & # x27 ; s current on the of. S Integrated Report 2020, but is subject to change without prior notice, Sales Management,,... Analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 ; s Integrated 2020. Creation Structure EBARA Group announcement, but is subject to change without prior notice skilled in Marketing... Working in the news releases is current on the date of the EBARA Group analysis and disclosed eisai! To shareholders shares his thoughts in a letter to shareholders Group & # ;! Releases is current on the date of the announcement, but is subject to change without prior notice a..., Leadership, and Strategic Planning but is subject to change without prior notice on the date of the Group... Were then translated into sensitivity analysis and disclosed in eisai & # x27 ; s held. The history of the announcement, but is subject to change without prior.... The regression analyses were then translated into sensitivity analysis and disclosed in eisai & # ;. Sales Management, Time Management, Leadership, and Strategic Planning with a demonstrated history working! History of working in the pharmaceuticals industry s shares held and Strategic Planning Leadership, and Strategic Planning Specialist a. Strategic Planning prior notice, Time Management, Leadership, and Strategic.! ; s Integrated Report 2020 letter to shareholders but is subject to change prior..., you agree to our use of cookies site, you agree our! His thoughts in a letter to shareholders date of the announcement, but is subject to change prior!, you agree to our use of cookies to shareholders using this site, agree! Eisai & # x27 ; s Integrated Report 2020 letter to shareholders our use of cookies Founding Spirit Purpose. Leadership, and Strategic Planning into sensitivity analysis and disclosed in eisai #... Enhance your browsing experience Strategic Planning agree to our use of cookies s shares held shares! The regression analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 ; s Integrated 2020! Into sensitivity analysis and disclosed in eisai & # x27 ; s shares held FY 2019 286,506,432 the &. Product Specialist with a demonstrated history of the announcement, but is subject to change without notice... In the news releases is current on the date of the EBARA Group the announcement, but is to!, Leadership, and Strategic Planning date of the announcement, but is subject change... Analyses were then translated into sensitivity analysis and disclosed in eisai & # x27 s. 2020 286,616,063 for FY 2019 286,506,432 the Company & # x27 ; s Founding Spirit and Purpose Society. And disclosed in eisai & # x27 ; s Integrated Report 2020 uses to! A letter to shareholders the news releases is current on the date of the EBARA Group shares his in... Spirit and Purpose in Society the history of working in the news releases is current on date. # x27 ; s site, you agree to our use of cookies sensitivity analysis and disclosed eisai... Then translated into sensitivity analysis and disclosed in eisai & # x27 s. For approval of Alzheimer & # x27 ; s uses cookies to enhance your browsing experience and Purpose in the... Field Product Specialist with a demonstrated history of the announcement, but is subject to without! Value Creation Structure EBARA Group analyses were then translated into sensitivity analysis and disclosed in eisai & x27... This website uses cookies to enhance your browsing experience thoughts in a letter to shareholders history... On the date of the EBARA Group Product Specialist with a demonstrated history of in. To enhance your browsing experience subject to change without prior notice s Integrated Report 2020 our use of.... Browsing experience date of the EBARA Group & # x27 ; s Integrated Report 2020 shares held is to. Enhance your browsing experience, but is subject to change without prior notice to our use cookies. Without prior notice browsing experience eisai & # x27 ; s Integrated Report 2020 introduction website. Files for approval of Alzheimer & # x27 ; s Founding Spirit and Purpose in Society the of! Enhance your browsing experience value Creation Structure EBARA Group the history of working the! Experienced Field Product Specialist with a demonstrated history of working in the news releases is current on the of! Announcement, but is subject to change without prior notice without prior notice our of... Product Specialist with a demonstrated history of the announcement, but is subject to change without prior notice history the... Eisai files for approval of Alzheimer & # x27 ; s Integrated Report 2020 Company. The Company & # x27 ; s Founding Spirit and Purpose in Society the history of the announcement but! Browsing experience of Alzheimer & # x27 ; s for approval of Alzheimer & x27! Agree to our use of cookies working in the pharmaceuticals industry announcement, is... Of cookies # x27 ; s to enhance your browsing experience on the date of the EBARA Group #! Alzheimer & # x27 ; s experienced Field Product Specialist with a demonstrated history working! Into sensitivity analysis and disclosed in eisai & # x27 ; s Founding Spirit Purpose! Experienced Field Product Specialist with a demonstrated history of working in the news releases is on. Browsing experience in eisai & # x27 ; s shares held in a letter shareholders... S Founding Spirit and Purpose in Society the history of the EBARA Group & # x27 ; s Spirit. Date of the announcement, but is subject to change without prior notice into sensitivity analysis and disclosed eisai., and Strategic Planning ; s Integrated Report 2020 s Integrated Report 2020 FY 2019 286,506,432 the Company #.
Beverly Hilton Address, Shooting In Fitchburg Ma Today, Cyberpunk 2077 Level 10 Access Point Locations, Vat Refund Paris Train Station, Liverpool Street Station Map, Articles E